Postnatal Corticosteroids To Prevent Bronchopulmonary Dysplasia.
Journal
NeoReviews
ISSN: 1526-9906
Titre abrégé: Neoreviews
Pays: United States
ID NLM: 101085360
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
31
10
2023
Statut:
ppublish
Résumé
Bronchopulmonary dysplasia (BPD) is a common, severe chronic respiratory disease that affects very preterm infants. In utero and postnatal exposure to proinflammatory stimuli contribute to the pathophysiology of BPD. Corticosteroids, because of their potent anti-inflammatory properties, may decrease respiratory morbidity and reduce the risk of BPD in very preterm infants. However, these medications can have adverse effects on the developing brain and other organ systems. This review examines current evidence on the risks and benefits of postnatal corticosteroids used to prevent BPD in preterm infants.
Identifiants
pubmed: 37907402
pii: 194500
doi: 10.1542/neo.24-11-e691
doi:
Substances chimiques
Glucocorticoids
0
Dexamethasone
7S5I7G3JQL
Adrenal Cortex Hormones
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e691-e703Informations de copyright
Copyright © 2023 by the American Academy of Pediatrics.